PMID- 33923759
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240401
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 13
IP  - 8
DP  - 2021 Apr 16
TI  - Multicenter Analysis of Treatment Outcomes for Systemic Therapy in Well 
      Differentiated Grade 3 Neuroendocrine Tumors (NET G3).
LID - 10.3390/cancers13081936 [doi]
LID - 1936
AB  - Well-differentiated grade 3 neuroendocrine tumors (NET G3) have been 
      distinguished from poorly differentiated neuroendocrine carcinomas (NEC) in the 
      most current WHO classifications. Commonly applied first-line chemotherapy 
      protocols with cisplatin or carboplatin in combination with etoposide (PE) are 
      less effective in NET G3 than NEC. Suggested alternative treatment protocols have 
      not been studied in first-line therapy of NET G3 so far. We performed a 
      retrospective analysis of patients with NET G3 in the databases of 3 German 
      cancer centers. Out of 142 patients, 136 patients received palliative first-line 
      therapy: overall response rate (ORR) was 35.1% for PE (n = 37), 56.4% for FOLFOX 
      (n = 39), 27.3% for temozolomide/capecitabine (TEM/CAP) (n = 22), 45.0% for 
      streptozotocin/5-fluorouracil (STZ/5-FU) (n = 20), and 16.7% for other (n = 18). 
      Median progression-free survival (PFS) for PE was 6.9 months. Compared to PE, PFS 
      in the other treatment groups was 6.9 months for FOLFOX (p = 0.333), 12.0 months 
      for TEM/CAP (p = 0.093), 4.8 months for STZ/5-FU (p = 0.919), and 14.1 months for 
      other (p = 0.014). In a univariate setting, all non-PE patients combined showed a 
      significantly prolonged PFS vs. PE (9.0 months; p = 0.049) which could not be 
      confirmed in a multivariate analysis. In conclusion, NET G3 with FOLFOX showed 
      the highest ORR, and with TEM/CAP showed the longest PFS. Further prospective 
      evaluation of the optimal therapeutic strategy for this tumor entity is needed.
FAU - Apostolidis, Leonidas
AU  - Apostolidis L
AUID- ORCID: 0000-0002-6358-8206
AD  - National Center for Tumor Diseases (NCT) Heidelberg, Department of Medical 
      Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
FAU - Dal Buono, Arianna
AU  - Dal Buono A
AD  - Department of Gastroenterology and Hepatology, Charite University Medicine, 13353 
      Berlin, Germany.
FAU - Merola, Elettra
AU  - Merola E
AD  - Department of Gastroenterology and Hepatology, Charite University Medicine, 13353 
      Berlin, Germany.
FAU - Jann, Henning
AU  - Jann H
AD  - Department of Gastroenterology and Hepatology, Charite University Medicine, 13353 
      Berlin, Germany.
FAU - Jager, Dirk
AU  - Jager D
AD  - National Center for Tumor Diseases (NCT) Heidelberg, Department of Medical 
      Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
FAU - Wiedenmann, Bertram
AU  - Wiedenmann B
AUID- ORCID: 0000-0002-7890-2552
AD  - Department of Gastroenterology and Hepatology, Charite University Medicine, 13353 
      Berlin, Germany.
FAU - Winkler, Eva Caroline
AU  - Winkler EC
AD  - National Center for Tumor Diseases (NCT) Heidelberg, Department of Medical 
      Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
FAU - Pavel, Marianne
AU  - Pavel M
AD  - Department of Gastroenterology and Hepatology, Charite University Medicine, 13353 
      Berlin, Germany.
AD  - Department of Medicine 1, Division of Endocrinology, Friedrich Alexander 
      University Erlangen-Nuremberg, 91054 Erlangen, Germany.
LA  - eng
PT  - Journal Article
DEP - 20210416
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC8073753
OTO - NOTNLM
OT  - NET G3
OT  - chemotherapy
OT  - first-line
OT  - neuroendocrine carcinoma
OT  - neuroendocrine tumor
OT  - peptide receptor radionuclide therapy
OT  - systemic therapy
COIS- The authors declare no conflict of interest.
EDAT- 2021/05/01 06:00
MHDA- 2021/05/01 06:01
PMCR- 2021/04/16
CRDT- 2021/04/30 01:26
PHST- 2021/03/02 00:00 [received]
PHST- 2021/03/28 00:00 [revised]
PHST- 2021/04/14 00:00 [accepted]
PHST- 2021/04/30 01:26 [entrez]
PHST- 2021/05/01 06:00 [pubmed]
PHST- 2021/05/01 06:01 [medline]
PHST- 2021/04/16 00:00 [pmc-release]
AID - cancers13081936 [pii]
AID - cancers-13-01936 [pii]
AID - 10.3390/cancers13081936 [doi]
PST - epublish
SO  - Cancers (Basel). 2021 Apr 16;13(8):1936. doi: 10.3390/cancers13081936.